Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study
by
Albert U, Aguglia E, Maina G, Bogetto F.
Anxiety and Mood Disorders Unit,
Department of Neurosciences,
University of Turin, Turin
(Drs. Albert, Maina, and Bogetto)
and the Psychiatric Clinic, University of Trieste, Trieste
(Drs. Albert and Aguglia), Italy.
J Clin Psychiatry 2002 Nov;63(11):1004-11


ABSTRACT

BACKGROUND: The objective of this study was to investigate, in a single-blind manner over a period of 12 weeks, the efficacy and tolerability of venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder (OCD). METHOD: Patients with a DSM-IV diagnosis of OCD and a Yale-Brown Obsessive Compulsive Scale (YBOCS) score >/= 16 were randomly assigned to receive venlafaxine, 225 to 350 mg/day (26 patients), or clomipramine, 150 to 225 mg/day (47 patients), for 12 weeks, with dosage adjustments according to tolerability and response to treatment. All patients were medication-free from at least 2 months prior to study enrollment. Efficacy measures were the YBOCS and the Clinical Global Impressions scale (CGI), which were completed at baseline and every 4 weeks.We defined responders as patients who had an improvement from baseline in YBOCS score of >/= 35% and a CGI score < / = 2. An investigator who was blinded to patients' current medication administered rating scales independently. Moreover, patients were instructed not to reveal their current treatment to this investigator. RESULTS: Twenty-five patients in the venlafaxine group and 40 in the clomipramine group completed the 12-week trial. Responder rates at the end of the 12 weeks were 36% for venlafaxine (9/25) versus 50% for clomipramine (20/40) according to the visitwise analysis and 34.6% (9/26) for venlafaxine versus 42.6% (20/47) for clomipramine according to the last-observation-carried-forward analysis, with no statistically significant difference between the 2 drugs. Adverse experiences were reported by 61.5% of patients receiving venlafaxine (16/26) and by 91.5% of those receiving clomipramine (43/47). CONCLUSION: Our results indicate that venlafaxine might be as efficacious as clomipramine in the acute treatment of OCD, with fewer side effects.
Options
Venlafaxine v SSRIs
Venlafaxine (Effexor)
Venlafaxine compared
Venlafaxine v fluoxetine
Clomipramine (Anafranil)
High-dose venlafaxine XL
Venlafaxine pharmacology
Venlafaxine plus bupropion
Venlafaxine and depression
Venlafaxine and neuropeptides
Venlafaxine and major depression
Venlafaxine versus paroxetine for OCD
Venlafaxine ER for generalized anxiety disorder (GAD)
OCD and selective serotonin reuptake inhibitors (SSRIs)
Venlafaxine (Effexor) for treatment-resistant depression
February 2008: FDA licenses antidepressant desvenlafaxine (Pristiq)


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family